Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2023

Genmab — December 2023

Planlagt Fastgjort Låst Flyttet Genmab
860 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #88

    Jo og det er jo også muligt at ikke alle midler benyttes i alle indikationer. Men det må være positiv, at forsøget udvides.

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #89

      Pointen var vel blot, at forsøget er komplekst 🙂

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #90

        Godmorgen. 🙂

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #91

          Capital Increase in Genmab as a Result of Employee Warrant Exercise https://www.proinvestor.com/investornyt/1086639/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Stroka
            wrote on sidst redigeret af
            #92

            God morgen 🙂

            1 Reply Last reply
            0
            • K Offline
              K Offline
              Klarussen
              wrote on sidst redigeret af
              #93

              Godmorgen 🙂

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #94

                Hubon
                @Hubon

                UBS: Genmab - Potential path towards novel IO, upgrade to Buy
                Upgrade: RATING: Buy (Neutral); PT: 2800 (3000);
                The largely ignored oncology pipeline could be an alternative, if not a better, solution for Darzalex cliff, with multiple catalysts ahead showing its potential. https://twitter.com/Hubon/status/1732303871257559233

                1 Reply Last reply
                0
                • H Offline
                  H Offline
                  Hen
                  wrote on sidst redigeret af
                  #95

                  Onsdag er der også analysenyt om Genmab, der har fået løftet anbefalingen hos UBS til "køb" fra tidligere "neutral". Kursmålet på 2800 kr. fastholdes og indikerer et potentiale på 27 pct. i forhold til tirsdagens lukkekurs for aktien på 2197 kr. .\˙ MarketWire

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #96

                    ESMO Immuno-Oncology 2023 Poster online- HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo https://cslide.ctimeetingtech.com/immuno23hybrid/attendee/confcal/presentation/list?q=148P+ "A first-in-human clinical trial is planned " I am assuming this is the #6 in the BioNTech cooperation.

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #97

                      ESMO Immuno-Oncology 2023 Poster - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress https://cslide.ctimeetingtech.com/immuno23hybrid/attendee/confcal/presentation/list?q=160TiP+

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #98

                        Genmab hæves til "køb" hos schweizisk storbank https://www.proinvestor.com/investornyt/1086822/genmab-haeves-til-kob-hos-schweizisk-storbank

                        1 Reply Last reply
                        0
                        • K Offline
                          K Offline
                          Klarussen
                          wrote on sidst redigeret af
                          #99

                          På tide

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #100

                            Sounds promissing, “ encouraging early clinical activity, including complete responses”.

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #101

                              Plural CRs in heavy treated pts. Very interesting !

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #102

                                agree, very early ofcourse, but the news we are getting so far seems promising !

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #103

                                  Doesn't this support our thinking yesterday, that the expansion of trial pts. is a possitiv sign ?

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #104

                                    I would think so, yes. Let's hope we'll get some comments on it next week.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #105

                                      "OX40 has been implicated in the pathologic cytokine storm associated with certain viral infections, including the H5N1 bird flu" If it doesn't work in solid tumors ; Biontech knows how to create vaccins 😉 https://en.wikipedia.org/wiki/CD134

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #106

                                        I find it comforting that BioNTech is willing to try the second Hexabody. After all, the technology has not yet been proven. But it would not surprise me if they have also seen the data on Hexabody-DR5/DR5 . Doubt they are allowed to see Hexabody-CD38 data early though.

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #107

                                          Genmab har ændret gen1046 til acasunlimab på deres hjemmeside, men har (endnu) ikke ændret gen1042. Så vi mangler den endelige beslutning.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper